Background: Coronary heart disease is one of the main causes of
Mortality. Many biological indicators have been used to predict the prognosis of
patients with coronary heart disease. The ratio of serum globulin to albumin
(GAR) has been used to predict the prognosis of patients with various cancers. It
has been proven that GAR is related to the prognosis of patients with
stroke. However, GAR’s role in cardiovascular disease remains unclear. Our
purpose was to investigate the predictive value of GAR on clinical outcomes in
post-percutaneous coronary intervention (PCI) patients with coronary artery
disease (CAD). Methods: From Dec. 2016 to Oct. 2021, a total of 14,994
patients undergoing PCI patients admitted to the First Affiliated Hospital of
Xinjiang Medical University were divided into high GAR group (GAR 0.76, n
= 4087) and low GAR group (GAR 0.76, n = 10,907). The incidence of adverse
outcomes including all-cause mortality (ACM), cardiovascular mortality (CM),
major adverse cardiovascular events (MACE) and major adverse cardiovascular and
cerebrovascular events (MACCE) was compared between the two groups. Multivariate
Cox regression was used to adjust for the effects of confounding factors, while
hazard ratios (HRs) and 95% confidence intervals (95% CI) were calculated.
Median follow-up time was 24 months. Results: Compared with the low GAR
group, the high GAR group had significantly higher incidence of ACM (6.5% vs.
1.7%, p 0.001); CM (4.9% vs. 1.2%, p 0.001), MACE
(10.5% vs. 6.7%, p 0.001), and MACCE (11.3% vs. 7.5%, p 0.001). Cox regression analysis showed the patients in the high GAR group had
a 1.62-fold increased risk for ACM (HR = 2.622, 95% CI: 2.130–3.228, p 0.01), a 1.782-fold increased risk for CM (HR = 2.782, 95% CI: 2.180–3.550,
p 0.01). There was a 37.2% increased risk for MACE (HR = 1.372,
95% CI: 1.204–1.564, p 0.01), and 32.4% increased risk for MACCE
(HR = 1.324, 95% CI: 1.169–1.500, p 0.01), compared to the
patients in the low GAR group. Conclusions: The present study suggested
that post-PCI CAD patients with higher GAR presented significantly increased
mortality and adverse events GAR level at admission may 296 be considered as part
of risk stratification when PCI is possible in patients with coronary heart
disease. Clinical Trial Registration: The detailed information of the PRACTICE
study has been registered on http://Clinicaltrials.gov (Identifier: NCT05174143).
